← All Pages
stock

Novo Nordisk

30m ago
-0.20
Lean Bear
NVO Price
$48.94
+0.10%
Market Cap
$216.5B
P/E Ratio
11.7
52W Range
$35.12 - $71.80
Dividend Yield
3.63%
Revenue Growth
24.0%
Upcoming
4Q2025 FDA Decision for Ozempic (semaglutide 1 mg & 2 mg) in T2DM and PAD
4Q2025 FDA Decision for Wegovy SC (semaglutide) in HFpEF and Obesity
4Q2025 FDA Decision for Oral Wegovy 25 mg
Drivers
Dr Reddy's delay provides minor relief but oral script trends and Lilly pill traction underscore margin compression risks
Trend
06-29
06-29
07-02
07-08
07-08
07-09
07-09
Generic supply hiccups and oral GLP-1 slowdown highlight near-term volatility amid rising competition from Lilly and others.
Novo Nordisk continues to advance oral semaglutide globally while facing intensifying competition and pricing scrutiny. A new telehealth distribution partnership with Hims & Hers signals potential volume tailwinds, though cybersecurity risks and patent timelines remain watchpoints. Broader GLP-1 market growth persists but with signs of payer pushback.
Background
Tracking began on 2026-03-20.
Your thesis: Bearish medium-term: GLP-1 competition from Lilly and Amgen will compress margins despite market growth
Recent Developments
Novo Nordisk launches Awiqli once-weekly insulin in India 7h ago
Neutral: Diversifies revenue beyond GLP-1 obesity focus but does not directly impact the core bearish thesis on GLP-1 competition and margins.
NewsMobile India
Dr Reddy's delays semaglutide supply due to active ingredient issue 7h ago
Challenges thesis: Temporary delay in generic supply could ease near-term pricing pressure on branded GLP-1s like Ozempic/Wegovy, potentially supporting margins despite broader competition.
Reuters
Novo Nordisk launches digital Type 2 diabetes support program in Germany 1d ago
Neutral: Digital tools may aid patient retention and adherence but represent incremental support rather than a core competitive differentiator against Lilly or Amgen.
X post by @investseekers
Wegovy pill potential Australia approval by Christmas 2026 1d ago
Neutral: International expansion supports volume growth but does not offset U.S./EU pricing and competition pressures central to the bearish view.
X post by @steady_profits
Novo Nordisk shares dip on GLP-1 pill prescription slowdown 1d ago
Reinforces thesis: Slowing oral pill uptake amid intensifying competition highlights margin compression risks despite overall market growth.
Yahoo Finance
Novo Nordisk advances next-generation obesity pipeline via Chinese biotech partnership targeting retatrutide-like efficacy 1d ago
Challenges thesis: Pipeline progress with high-efficacy candidates could help Novo defend market share and margins against Lilly and others longer-term.
X post by Aktieland
India GLP-1/fat-loss drug sales growth slows sharply to 2.3% in June after generics-driven spike 1d ago
Reinforces thesis: Slowing growth in India underscores pricing pressure and competition from generics, supporting the bearish view on margin compression despite overall market expansion.
Bloomberg
Kailera Therapeutics oral GLP-1 meets trial goal but faces high nausea rates 1d ago
Reinforces thesis: Competitor setbacks on side effects underscore broader GLP-1 tolerability issues that could favor established players like Novo but intensify overall market competition and pricing pressure.
Reuters
Novo Nordisk prioritizes Australia for oral Wegovy launch 1d ago
Neutral: Expands international oral GLP-1 footprint but does not directly address U.S. margin compression from Lilly/Amgen competition.
Investseekers on X / industry sources
Novo Nordisk to evaluate Vivani Medical semaglutide implant 2d ago
Challenges thesis: Early-stage implant technology could differentiate Novo's offerings and support long-term market position amid competition, potentially mitigating some margin pressure through innovation in delivery methods.
X posts and market reports
News
product Novo Nordisk's Ozempic Pill Now Available in US - FDA-Approved Oral GLP-1 with Cardiovascular Benefits PR Newswire · 69d ago
regulatory FDA Criticizes Novo Nordisk for Serious Violations in Semaglutide Side Effect Reporting NBC News · NaNd ago
product Novo Nordisk Advances Amycretin to Phase 3 Trials for Weight Management and Diabetes GoodRx · 403d ago
product Wegovy Pill Demonstrates Superior Weight Loss Compared to Orforglipron Novo Nordisk · NaNd ago
regulatory FDA Warns of Serious Adverse Events from Compounded GLP-1 Drugs Including Semaglutide and Tirzepatide FDA · 343d ago
Themes
FDA Regulatory Milestones high
Generic Competition and Pricing Pressure high
Side effect reports and safety signals medium
GLP-1 Market Competition high
GLP-1 Market Expansion high
Movers
▼ AZN
-5.5% $178.82
▲ VKTX
+1.8% $40.66
▼ AMGN
-1.4% $362.70
▼ HIMS
-1.0% $35.70
▲ PFE
+0.8% $24.23
▲ NVO
+0.1% $48.94
Social Buzz
$NVO technical analysis and oral Wegovy rollout few hundred HIMS Novo Nordisk partnership for branded GLP-1s hundreds
Aktieland@Aktieland
Let it keep coming. 💪 Give us a powerful candle, reclaim the $50 level and close that gap. The news flow keeps improving, oral Wegovy is rolling out in the UK, and yet the stock is trading as if nothing is happening. Patience. $NVO
5 likes
Arb Terminal@arb_terminal
The Novo Nordisk partnership. $HIMS went from getting sued by Novo Nordisk to partnering with them. Wegovy and Ozempic now available directly through the Hims platform. 125,000+ Wegovy orders shipped in the first 6 weeks.
1 like
Watchlist
Oral Wegovy U.S. prescription trends
Key Players
■
Dr Reddy's Laboratories
Generic semaglutide supplier facing production delays
AZN AstraZeneca PLC
$178.82 -5.5%
VKTX Viking Therapeutics, Inc.
$40.66 +1.8%